Genomic Vision Signs a Distribution Agreement with AmCare Genomics Laboratory in China for Its FSHD Diagnostic Assay
October 19 2017 - 1:30AM
Business Wire
The company accelerates its strategic
development in China, the largest market in the world with 70,000
to 140,000 people suffering from Facioscapulohumeral muscular
dystrophy
Regulatory News:
Genomic Vision (FR0011799907 – GV), a company specialized
in the development of diagnostic tests for the early detection of
cancers and hereditary diseases, and applications for life sciences
research, today announced that it has signed an exclusive
distribution agreement with AmCare Genomics Laboratory to market
the FSHD diagnostic assay in China.
“We are thrilled to have acquired Genomic Vision’s technology
and signed an exclusive distribution agreement for the FSHD
diagnostic assay in China. Thanks to our large network and
connections within the neurology and FSHD communities in China, we
are confident in raising significant awareness among physicians and
patients on the most powerful diagnostic test for FSHD,”
commented Dr. Victor Wei Zhang, CEO of AmCare Genomics
Laboratory.
“Following our distribution deal with APG Bio Ltd last June,
this marketing agreement with AmCare represents a second major
milestone in our global strategy to enter new markets in Asia. In
China, it is estimated that 70,000 to 140,000 people are affected
with FSHD. Moreover, the field of genomics and genetic testing is
extremely developed, notably in large cities. We are convinced that
our robust diagnostic technology will provide great benefits to
families and patients. We look forward to deploying our FSHD
solution in China and to strengthening our presence in the country
through this valuable partnership,” added David Del Bourgo,
Marketing & Sales Director of Genomic Vision.
Facioscapulohumeral muscular dystrophy (FSHD) is the third most
prevalent muscular hereditary myopathy worldwide. This genetic
disease manifests as atrophy and weakness in the face, shoulders,
and ambulatory muscles. There is great variability in clinical
severity, from a severe infantile form to individuals who remain
asymptomatic throughout their lives. This autosomal dominant
disease is thought to affect 1 in 10,000 to 1 in 20,000 people. The
actual number of individuals with FSHD worldwide is 870,000, which
could be significantly higher due to undiagnosed cases. About 70%
of FSHD patients inherit the disease from a parent, while 30% of
the cases are sporadic and associated to de novo mutations.
ABOUT GENOMIC VISION
GENOMIC VISION is a company specialized in the development of
diagnostic solutions for the early detection of cancers and serious
genetic diseases and tools for life sciences research. Through the
DNA Molecular Combing, a strong proprietary technology allowing to
identify genetic abnormalities, GENOMIC VISION stimulates the
R&D productivity of the pharmaceutical companies, the leaders
of the diagnostic industry and the research labs.
The Company develops a robust portfolio of diagnostic tests
(breast, ovarian and colorectal cancers, myopathies) and analysis
tools (DNA replication, biomarkers discovery, gene editing quality
control). Based near Paris, in Bagneux, the Company has
approximately 60 employees. GENOMIC VISION is a public listed
company listed in compartment C of Euronext’s regulated market in
Paris (Euronext: GV - ISIN: FR0011799907). For further information,
please visit www.genomicvision.com
Member of CAC® Mid & Small and CAC®
All-Tradable indexes
FORWARD LOOKING STATEMENT
This press release contains implicitly or explicitly certain
forward-looking statements concerning Genomic Vision and its
business.
Such forward-looking statements are based on assumptions that
Genomic Vision considers to be reasonable. However, there can be no
assurance that such forward-looking statements will be verified,
which statements are subject to numerous risks, including the risks
set forth in the “Risk Factors” section of the annual financial
report dated April 29, 2016, available on the web site of Genomic
Vision (www.genomicvision.com) and to the development of economic
conditions, financial markets and the markets in which Genomic
Vision operates. The forward-looking statements contained in this
press release are also subject to risks not yet known to Genomic
Vision or not currently considered material by Genomic Vision. The
occurrence of all or part of such risks could cause actual results,
financial conditions, performance or achievements of Genomic Vision
to be materially different from such forward-looking
statements.
This press release and the information contained herein do not
constitute and should not be construed as an offer or an invitation
to sell or subscribe, or the solicitation of any order or
invitation to purchase or subscribe for Genomic Vision shares in
any country. The distribution of this press release in certain
countries may be a breach of applicable laws. The persons in
possession of this press release must inquire about any local
restrictions and comply with these restrictions.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20171018006617/en/
Genomic VisionAaron BensimonCo-founder, Chairman &
CEOTel.: +33 1 49 08 07
50investisseurs@genomicvision.comorUlysse
CommunicationPress RelationsBruno ArabianTel.: +33 1 81
70 96 30barabian@ulysse-communication.comorNewCapInvestor
RelationsDušan Orešanský / Emmanuel HuynhTel.: +33 1 44 71 94
92gv@newcap.eu
Goldfield (AMEX:GV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Goldfield (AMEX:GV)
Historical Stock Chart
From Apr 2023 to Apr 2024